Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis by Ammann, Sandra et al.
Sandra Ammann, 
Kai Lehmberg, 
Udo zur Stadt, 
Christian Klemann, 
Sebastian F. N. Bode, 
Carsten Speckmann, 
Gritta Janka, 
Katharina Wustrau, 
Mirzokhid Rakhmanov, 
Ilka Fuchs, 
Hans C. Hennies, 
Stephan Ehl, 
Phone +49-761-27077550
Email stephan.ehl@uniklinik-freiburg.de
the HLH study of the GPOH
Martina
Ahlmann,
Roland
Ammann,
Uta
Behrends,
1,2
3
4
1
1,5
1,5
3
3
1,6
1
7,8,9
1✉,5
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=Ewaz55...
1 of 29
Rita
Beier,
Horst
von
Bernuth,
Karin
Beutel,
Birgit
Burkhardt,
Gunnar
Cario,
Carl-Friedrich
Classen,
Matthias
Dürken,
Martin
Ebinger,
Johann
Greil,
Ute
Groß-Wieltsch,
Bernd
Gruhn,
Wolfgang
Holter,
Patrick
Hundsdörfer,
Ingrid
Kühnle,
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=Ewaz55...
2 of 29
Norbert
Jorch,
Reinhard
Kolb,
Jörn-Sven
Kühl,
Britta
Maecker,
Roland
Meisel,
Milen
Minkov,
Ingo
Müller,
Tim
Niehuis,
Jana
Pachlopnik-Schmid,
Arnulf
Pekrun,
Aram
Prokop,
Johannes
Rischewski,
Irene
Schmid,
Ansgar
Schulz,
Paul-Gerhardt
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=Ewaz55...
3 of 29
Schlegel,
Michael
Schündeln,
Markus
Seidel,
Thorsten
Simon,
Jan
Sörensen,
Martin
Chada,
Meinolf
Suttorp,
Wilhelm
Woessmann,
Center for Chronic Immunodeficiency, Medical Center, Faculty of
Medicine, University of Freiburg, Freiburg, Germany AQ1
Faculty of Biology, University Freiburg, Freiburg, Germany
Division of Pediatric Stem Cell Transplantation and
Immunology, University Medical Center Hamburg
Eppendorf, Hamburg, Germany
Center for Diagnostic, University Medical Center Hamburg
Eppendorf, Hamburg, Germany
Center for Pediatrics and Adolescent Medicine, University of
Freiburg, Freiburg, Germany
Center for Human Genetics and Laboratory Diagnostics
(AHC), Martinried, Germany
Cologne Center for Genomics, University of Cologne, Cologne, Germany
Cologne Excellence Cluster on Cellular Stress Responses in Aging-
1
2
3
4
5
6
7
8
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=Ewaz55...
4 of 29
Associated Diseases (CECAD), University of Cologne, Cologne, Germany
Department of Biological Sciences, University of
Huddersfield, Huddersfield, UK
We  report  our  experience  in  using  flow  cytometry-based  immunological
screening prospectively as a decision tool for the use of genetic studies in
the  diagnostic  approach  to  patients  with  hemophagocytic
lymphohistiocytosis  (HLH).  We  restricted  genetic  analysis  largely  to
patients  with  abnormal  immunological  screening,  but  included  whole
exome  sequencing  (WES)  for  those  with  normal  findings  upon  Sanger
sequencing.  Among  290  children  with  suspected  HLH analyzed  between
2010 and 2014 (including 17 affected, but asymptomatic siblings), 87/162
patients  with  “full”  HLH and  79/111  patients  with  “incomplete/atypical”
HLH  had  normal  immunological  screening  results.  In  10  patients,
degranulation  could  not  be  tested.  Among  the  166  patients  with  normal
screening, genetic analysis was not performed in 107 (all with uneventful
follow-up),  while  154  single  gene  tests  by  Sanger  sequencing  in  the
remaining 59 patients only identified a single atypical CHS patient.  Flow
cytometry  correctly  predicted  all  29  patients  with  FHL-2,  XLP1  or  2.
Among  85  patients  with  defective  NK  degranulation  (including  13
asymptomatic  siblings),  70  were  Sanger  sequenced resulting  in  a  genetic
diagnosis in 55 (79%). Eight patients underwent WES, revealing mutations
in  two  known  and  one  unknown  cytotoxicity  genes  and  one  metabolic
disease.  FHL3  was  the  most  frequent  genetic  diagnosis.  Immunological
screening  provided  an  excellent  decision  tool  for  the  need  and  depth  of
genetic  analysis  of  HLH  patients  and  provided  functionally  relevant
information  for  rapid  patient  classification,  contributing  to  a  significant
reduction in the time from diagnosis to transplantation in recent years.
Hemophagocytic lymphohistocytosis
diagnosis
flow cytometry
degranulation
whole exome sequencing
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Abbreviations
CHS Chediak-Higashi syndrome
CTL cytotoxic T cells
FHL familial hemophagocytic lymphohistiocytosis
GPOH group of the Society for Pediatric Oncology and Hematology
GS2 Griscelli syndrome type 2
HLH hemophagocytic lymphohistiocytosis
HPS2 Hermansky-Pudlak syndrome type 2
HSCT hematopoietic stem cell transplantation
LCH Langerhans cell histiocytosis
MAS-HLH Macrophage-activation syndrome
NGS next-generation sequencing
NK cell natural killer cell
PID primary immunodeficiency
WES whole exome sequencing
XLP X-linked lymphoproliferate syndrome
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Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder
characterized by severe hyperinflammation. HLH is not a single disease, but a
characteristic syndrome that may develop in the context of various underlying
conditions [1]. Genetic diseases affecting lymphocyte cytotoxicity, in which
HLH is the key manifestation, are summarized as familial HLH (FHL2–5). In
other genetic conditions affecting lymphocyte cytotoxicity, HLH can be one
manifestation of a more complex syndrome (Griscelli syndrome type II (GS2),
Chediak-Higashi syndrome (CHS), Hermansky-Pudlak syndrome type II
(HPS2)) [2]. Two additional primary immunodeficiencies, X-linked
lymphoproliferative disease type I and II, are associated with a high risk of
HLH, particularly following EBV infection [3]. HLH developing in any of
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these genetic diseases is usually termed primary (1°) HLH [4, 5]. In addition,
there are “secondary” (2°) or “sporadic” forms of HLH, frequently induced by
infections, in the absence of a biallelic or hemizygous defect in a gene
associated with 1°HLH. 2°HLH also occurs in malignant, autoinflammatory,
or autoimmune diseases, frequently also triggered or enhanced by infections
[6]. Finally, 2°HLH occurs in genetic diseases, in which HLH is a rare, but
nevertheless associated manifestation. This includes primary
immunodeficiencies (PID) [7] and metabolic diseases [6].
The distinction between 1° and 2°HLH has important clinical implications
because most patients with 1°HLH require hematopoietic hematopoietic stem
cell transplantation (HSCT) for most patients with 1°HLH [8, 9, 10, 11].
Rapid identification of 1°HLH patients is paramount to facilitate immediate
initiation of HSCT preparation. We and others have previously demonstrated
the high sensitivity and specificity of intracellular protein staining and NK-
cell and cytotoxic T cell (CTL) degranulation testing for identifying patients
with 1°HLH [12, 13, 14, 15]. However, to which extent these tests can be used
in clinical practice to reduce genetic screening, to direct more extensive
genetic analysis including exome sequencing, or to expedite diagnosis has not
been explored. Moreover, a recent paper speculated that with increased use of
high throughput sequencing, immunological tests might be fully abandoned
[16]. Thus, the significance of immunological evaluation of HLH patients
remains debated.
We prospectively analyzed whether immunological studies can be used as a
decision tool for the need and extent of genetic studies in 290 children
referred for suspected HLH to the German HLH reference centers.
Immunological screening performed before targeted sequencing of HLH-
associated genes led to substantial reduction of genetic investigations and
provided direct validation of the functional relevance of genetic findings. It
was also used to identify patients with indication for whole exome sequencing
(WES) on the basis of clear functional abnormalities, which helped resolve a
few additional cases. This clinical practice provided functionally relevant
information for treatment intensity and decisions on HSCT in patients with
suspected HLH within 72 h. It has contributed to a significant reduction in the
time from HLH diagnosis to HSCT in patients with primary HLH.
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The HLH study group of the Society for Pediatric Oncology and Hematology
in Germany, Austria, and Switzerland (GPOH) is coordinated by two
reference centers (Hamburg and Freiburg). About 80–90% of children with
suspected HLH in German hospitals are reported. Children with macrophage
activation syndrome (MAS) in autoimmune or autoinflammatory diseases are
usually only reported following hematological consultation for exclusion of
1°HLH or specific treatment issues.
All patients below age 16 reported to the HLH study for suspected HLH
between 01/2010 and 12/2014 were included. Twenty international patients,
mainly from Turkey and Eastern Europe, were included into the analysis of
the diagnostic algorithm, but excluded from epidemiological calculations.
Informed consent was obtained according to the institutional review board
approval (University of Freiburg ethics committee’s protocol numbers 143/12
and 40/08).
Patients were classified as follows: (1) patients fulfilling at least 5/8 clinical
criteria for HLH (“full” HLH), (2a) patients with sufficient documentation to
state that they fulfilled less than 5/8 criteria (“incomplete HLH”), (2b)
patients with liver failure or inflammatory CNS disease which are no formal
HLH criteria, but prompted evaluation for 1°HLH (“atypical HLH”), (3)
patients without any HLH symptoms, referred because of an affected relative
or albinism. Of these, we included only those with a final 1°HLH diagnosis
(“asymptomatic genetic disease”), (4) patients with insufficient
documentation to state whether they fulfilled 5/8 criteria (“incomplete clinical
information”). This mostly concerned patients referred for immunological
screening, for which “incomplete/atypical” HLH was a remote differential
diagnosis. In these patients, the referring physicians had frequently not
quantified all HLH criteria at the time of requesting immunological analysis,
which did not allow judgment, whether at least 5/8 criteria were fulfilled.
Once provided with the negative immunological results, other diagnoses were
pursued and outcome of further lab tests and final patient diagnosis were not
reported to the HLH study group, leading to incomplete documentation.
Among 388 patients referred for immunological evaluation in the study
period, 98 patients were in this category leaving 290 patients for analyses.
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Degranulation assays with “fresh” (uncultured) and “activated” (incubated
with 100 U/ml IL-2 for 48–72 h) NK cells were performed as published using
protocol 1 [12]. Tests were repeated if the day control did not yield normal
results. Results were classified as normal (fresh assay > 10% or fresh assay
< 10% and activated assay > 35%) or defective (fresh assay < 10% and
activated assay < 35%) based on previously published receiver operating
characteristic analyses. In patients with abnormal protein stains, genomic
DNA was Sanger sequenced for mutations in PRF1 (FHL-2), SH2D1A
(XLP-1), or BIRC4A (XLP-2). Patients with abnormal or defective
degranulation were analyzed in parallel for mutations in UNC13D (FHL-3),
including selected intronic regions [17, 18], and STXBP2 (FHL-5), followed
by analysis of STX11 [19]. In patients with albinism, hair morphology and
blood smear abnormalities guided the order of sequencing of RAB27A (GS-2),
LYST (CHS), and AP3B1 (HPS2). In the course of the study, we changed our
policy and sequenced RAB27A also in patients without these manifestations
[20]. Primer sequences are available upon request (U. zur Stadt). Exome
sequencing was performed in unresolved cases with defective fresh NK
degranulation as described [21]. Selected variants were confirmed by Sanger
sequencing.
Genetic variants were considered disease-causing (1°HLH), if they occurred
in a homozygous, compound heterozygous, or hemizygous X-linked form and
were shown to be functionally relevant by protein expression and/or
functional analysis and/or had been published as HLH-associated in another
patient. For patients with “full” HLH, we obtained follow-up information on
survival, relapse of HLH and final diagnostic classification by the treating
physician. Patients with a definite diagnosis of rheumatic disease, malignancy,
metabolic disease, or PID were classified as such independent of the time of
follow-up. Patients with HLH only associated with infection or HLH of
unclear cause were classified as 2°HLH, if they lacked relapse within a
follow-up period of at least 6 months.
To test whether time from clinical (not genetic) diagnosis of HLH to HSCT
had changed after the introduction of immunological screening, we compared
the study period (2010–2014) to a previous 5-year period (2003–2008). For
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this, a competing risk analysis was performed with death prior to HSCT as
competing event, using R 3.1.0 (R Foundation for Statistical Computing,
Vienna Austria) [22].
Patients of the study cohort (2010–2014) with a diagnosis of primary HLH
who received an HSCT or died prior to HSCT were included in the analysis
(n = 38). Patients consecutively diagnosed with primary HLH between 2003
and 2008 were used for comparison (n = 38). However, in this cohort, we only
included patients with a genetic defect that was known at the time of
diagnosis (leading to exclusion patients with a retrospective diagnosis of
FHL5). Patients diagnosed in 2009 were not included as diagnostic procedures
were gradually modified during that year. Patients from outside Germany,
asymptomatic patients, and patients with XIAP deficiency were excluded in
both groups.
We analyzed 290 patients referred between January 2010 and December 2014.
This included 162 patients with “full HLH” (Fig. 1) and 111 patients with
“incomplete HLH” or atypical HLH (CNS inflammatory disease or liver
failure) (Fig. 2). We included 17 patients with asymptomatic genetic disease.
Fig. 1
Flow diagram of diagnostic evaluation of patients presenting with “full” HLH.
Details on individual sequencing decisions including WES are provided in the
text. 1 Perforin A91V mutations were not considered pathogenic. 2 Patient was
sequenced  because  of  pigmentation  abnormalities.  3  WES  was  restricted  to
patients with fresh NK degranulation < 5%
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Fig. 2
Flow  diagram  of  diagnostic  evaluation  of  patients  presenting  with
“incomplete/atypical”  HLH.  Details  on  individual  sequencing  decisions
including WES are provided in the text. 1 WES was restricted to patients with
fresh NK degranulation < 5%
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All patients were screened by flow cytometry for perforin expression and
male patients also for SAP or XIAP expression. Seven patients had reduced
(Fig. 3, middle panels) protein expression and 24 patients had absent protein
expression (Fig. 3, right panels). Disease-causing biallelic or hemizygous
mutations were detected in all of them, except for 2 who had heterozygous
perforin A91V mutations. Since normal protein expression has been reported
in patients with SAP missense mutations, patients with high clinical suspicion
for XLP were sequenced despite normal protein expression. However, in the
present cohort, none of the patients with a final diagnosis of FHL-2, XLP-1,
or XLP-2 had normal protein expression (Fig. 3, left panels).
Fig. 34
Degranulation assays can reduce genetic investigations in patients with “full”
HLH.  NK degranulation  was  analyzed  in  138  patients  with  “full”  HLH and
normal protein stainings. Left panel: fresh NK cell degranulation expressed as
delta  CD107a.  Shaded gray:  normal values;  dotted line:  cut-off  below which
genetic  disease  is  likely .  Right  panel:  results  of  genetic  analysis  in  the
indicated cohorts grouped by fresh NK degranulation results and the results of
stimulated NK degranulation This is Figure legend number 4. Sorry it is mixed up.
12
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Sixty-six patients with “full” HLH (41%) had fresh NK degranulation < 10%.
In 60 of these, we performed additional degranulation testing of PHA/IL-2
stimulated NK cells, while lack of material did not allow further tests in 6
patients (Fig. 2). Among the 47 patients with 0–5% fresh NK degranulation,
analysis of stimulated NK cells led to classification as “defective
degranulation” in 39 (abnormal + not done). All but 2 of these patients (with a
diagnosis of LCH and anaplastic lymphoma) were sequenced, leading to a
genetic diagnosis in 32/37 patients. Among the 19 patients with 5–10% fresh
NK degranulation (Fig. 4), 11 were classified as “defective degranulation”
(abnormal + not done), 7 of these were sequenced, and mutations were found
in 4. Four patients were not sequenced because of a diagnosis of SCID (1),
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lymphoma (2), and lack of material (1). Overall, Sanger sequencing revealed
disease-causing mutations in 34/44 patients with defective degranulation.
Fig. 43
Effective immunological screening by intracellular flow cytometry. a  Perforin
expression analysis in CD56+ NK cells. b Overlay of the fluorsecence signal of
CD3+ cells stained with anti-SAP (solid line) or an isotype control (scattered
line).  c  Overlay  of  the  fluorsecence  signal  of  CD3+ cells  stained  with  anti-
XIAP (solid line) or an isotype control (scattered line).  a–c  Sample plots  for
patients  with  normal,  reduced,  or  absent  protein  expression.  The  relative
number of patients showing the indicated pattern among all patients with the
respective  molecular  diagnosis  is  shown This  is  figure  legend  number  3.  Mixed
up
Seventy-two of the 142 patients with “full” HLH and normal protein
expression (51%) also had normal fresh NK degranulation, while this test was
not performed in 6 patients (Fig. 1, Fig. 4). In one patient, sequencing was
performed because of albinism and pathologic hair pigment distribution
revealed a diagnosis of CHS (details below). Among the other 71 patients, no
e.Proofing http://eproofing.springer.com/journals/printpage.php?token=Ewaz55...
14 of 29
genetic analysis was performed in 48, while 70 genes were sequenced in 23
patients because of the request of the referring physician. The monoallelic
A91V perforin mutation was detected in one patient with Langerhans cell
histiocytosis and EBV infection, and in one patient with genetically confirmed
osteopetrosis. All 71 patients were classified as 2° HLH or as lost to follow-
up on the following basis: 7 patients died in the acute phase of HLH, 3 of
them in the context of malignant disease, 2 with syndromic diseases, and 2 in
the context of EBV infection with negative genetic results. One patient had
CGD. Another 53 patients had a follow-up of > 6 months (median 2.4 years,
range 6 months to 4 years) without relapse. The remaining 11 patients (3 with
MAS) were lost to follow-up.
The 12 patients who were not sequenced and the 18 patients with negative
genetic results were classified as 2° HLH or lost to follow-up on the following
basis: 5 patients died, 3 from malignant disease, 1 from Wolman disease, and
one from unknown cause (Sanger sequenced in all known HLH-associated
genes). One patient had SCID. Twenty-two patients had no disease recurrence
within a median of 1.6-year follow-up (range 0.7–4.9 years). One patient had
a second HLH episode 2 years later but no mutation in known genes, while
one patient was lost to follow-up.
In the group with “incomplete/atypical” HLH, 7 of 111 patients had reduced
or absent expression of PRF1 (1), SH2D1A (2), or XIAP (4) (Fig. 2). Fresh
NK degranulation was analyzed in 100 of the remaining 104 patients, with a
normal result in 79 (79%) (Fig. 2, Fig. 5). In 26 of these, 52 genetic tests were
performed based on requests by the referring physicians. All were negative.
Twenty-five patients had fresh NK degranulation between 5 and 10% (Fig. 5).
In 7 of them including 1 with abnormal stimulated NK/degranulation, genetic
analysis was performed, but no mutation was found. Among 20 patients with
fresh NK degranulation between 0 and 5%, mutations were found in 6/8
patients with abnormal stimulated NK/CTL degranulation and 0/8 patients
where this second test was normal (Fig. 5). Table 1 shows details of the
patients with “incomplete/atypical” presentation in whom genetic testing
revealed 1°HLH.
Fig. 5
Degranulation  assays  can  reduce  genetic  investigations  in  patients  with
“incomplete/atypical”  HLH.  Patients  with  “incomplete/atypical”  HLH  and
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normal protein stainings were analyzed for NK degranulation. Left panel: fresh
NK cell degranulation results expressed as delta CD107a. Shaded gray: normal
values; dotted line: cut-off below which genetic disease is likely . Right panel:
results  of  genetic  analysis  in  the  indicated  cohorts  grouped  by  fresh  NK
degranulation  results  and  the  results  of  stimulated  NK degranulation  results.
Black and white indicate presence or absence of a genetic degranulation defect,
gray: no genetic investigations performed
Table 1
Patients with “incomplete” or “atypical” HLH and positive genetic testing
Pat# Finaldiagnosis
Clinical
presentation Mutation
Protein
expression
Age
at Trig
3947 FHL-2 CNS only homozygousc.208G > T absent 10.4 –
3778 FHL-3 CNS andincomplete
homozygous
c.1208C > T n.d 1.0 –
2834 FHL-3 CNS andincomplete
Not reported by
referring center n.d 5.1 –
12
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Pat# Finaldiagnosis
Clinical
presentation Mutation
Protein
expression
Age
at Trig
4389 FHL-5 incomplete homozygousc.781C > T n.d 0.4 –
2076 FHL-5 CNS andhepatitis
homozygous
c.1247(−1) G > C n.d 9.1 –
695 GS2 incomplete homozygousc.428 T > C n.d 4.0 EBV
1315 HPS2 incomplete homozygousc.2041G > T n.d 1.7 –
4385 XLP1 CNS andincomplete
hemizygous
c.199G > T absent 4.5 –
586 XLP1 incomplete hemizygousc.79G > A absent 7.8 unkn
2490 XLP2 incomplete hemizygousc.728_749del22 absent 12.3 unkn
866 XLP2 incomplete hemizygousc.997_1001DCAGAA absent 14.0 –
904 XLP2 incomplete hemizygousc.1141C > T absent 7.2 EBV
1059 XLP2 incomplete hemizygous c.1A > T reduced 9.6 EBV
Patients with defective fresh NK degranulation (< 5%), but no mutations in
1°HLH genes upon Sanger sequencing qualified for WES. In 12 of 20 patients
fulfilling these criteria (Figs. 4 and 5), WES was not performed because there
was insufficient material, the family denied consent or because the physician
did not want to pursue this option because a plausible diagnosis such as
malignancy or metabolic disease had been made (suppl. Tab. 2). Using WES,
a genetic diagnosis could be established in four patients from consanguineous
families (Table 2). In one patient with “full” HLH, we detected an unknown
homozygous inversion of 1.65 MB involving the gene UNC13D with intronic
breakpoints. This mutation had been missed in the conventional sequencing
procedure based on amplification of single exons, which had rendered normal
PCR products and sequences. Using WES, the breakpoints of this new
inversion were assigned to intron 25 of UNC13D, 110 bp downstream of exon
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25, and intron 3 of TTYH2. A Western blot analysis revealed complete
absence of the Munc13–4 protein (Suppl. Fig. 1), confirming FHL-3. The
second patient with “full” HLH had the homozygous mutation c.553delT
resulting in a frame shift in the gene encoding lysosomal acid lipase (LIPA)
and was diagnosed with Wolman disease, which is known to sometimes
present with an HLH phenotype [23]. 1°HLH was also diagnosed in two
patients with “incomplete/atypical” HLH. This included one patient with
GS-2, in whom RAB27A had initially not been sequenced because he lacked
albinism and hair abnormalities. The second patient carried a biallelic deletion
in the gene encoding AP-3δ. This patient was given the novel diagnosis of
HPS-10; details were reported elsewhere [21]. In four non-consanguineous
patients with “full” HLH, analysis of WES data did so far not yield a plausible
candidate gene.
Table 2
Patients analyzed by whole exome sequencing (WES)
Pat# HLH
Fresh
NK StimulatedNK/CTL
Con-
sang FH
Age
at Disease
2920 Full 0.35 Abnormal yes yes 0.3 FHL-3 UNC13D:c.24biallelic
1316 Full 0.67 n.d. yes no 0.5 ? ?
1996 Full 2.77 Normal no no 0.1 ? ?
1398 Full 3.22 Normal yes n.a. 0.2 LALDef LIPA:c.553de
2215 Full 0.7 Abnormal no yes 13 ? ?
710 Full 4.6 Abnormal no n.a. 0.1 ? ?
659 incompl 1.3 Abnormal yes no 3.1 HPS-10 AP3D1:c.356biallelic
3434 incompl 4.6 Normal yes yes 10.0 GS-2 RAB27A:c.19
FH family history, n.a. not available, n.d. not done
Overall, among the 290 patients referred for suspected HLH and sufficient
information for final disease classification, 162 had “full” HLH. Of these, 58
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patients (44 FHL2–5) had a final diagnosis of 1°HLH (35%), while 93
patients had 2°HLH (57%) (Fig. 6a). This included 12 patients with rheumatic
disease, 11 with malignancy, one patient each with common γ-chain
deficiency, X-linked chronic granulomatous disease and prolidase deficiency,
and 38 patients in whom an infection was the only associated clinical feature.
In 28 patients, no clear underlying condition was found. Eleven patients (8%)
were lost to follow-up. Notably, 1°HLH was also diagnosed in 32 patients in
the absence of “full” HLH (Fig. 6b). Of these, 15 (5 FHL) had
“incomplete/atypical” HLH and 17 (6 FHL) were asymptomatic at the time of
genetic diagnosis. This means that no more than 64% of patients with a
genetic disease predisposing to HLH (80% of patients with FHL2–5) were
actually diagnosed in a disease episode fulfilling the clinical HLH criteria.
Among patients with 1°HLH (Fig. 6c), FHL represented 64% with
predominance of FHL-3 (29%), followed by FHL-5 (17%) and FHL-2 (16%).
Albinism syndromes were diagnosed in 20% of patients, while 16% had XLP.
This distribution was similar if the analysis was restricted to the 81 patients
referred from German hospitals (not shown).
Fig. 6
Final classification of patients with “full  HLH” and clinical  presentation and
genetic diagnosis of patients with 1°HLH. Final classification of patients with
“full” HLH. The absolute number of patients with a given diagnosis is indicated
in the sections of the plot. PID  primary immunodeficiency, MAS  macrophage
activation syndrome, LTF  lost to follow-up. b  Clinical presentation of the 91
patients with a final diagnosis of 1°HLH. c  Genetic diagnosis of the patients
with 1°HLH
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To test whether time from clinical diagnosis of HLH to HSCT had changed
after the introduction of immunological screening, we compared the study
period (2010–2014) to a previous 5-year period (2003–2008). Time from
clinical diagnosis of acute HLH to HSCT was significantly shorter in the time
period after introduction of the screening algorithm (median 130 versus
206 days, p = 0.007, corrected for death prior to HSCT as competing event)
(Fig. 7).
Fig. 7
Expedited  HSCT  after  introduction  of  immunological  screening.  The
cumulative performance of HSCT over time after the clinical diagnosis of HLH
is  shown.  The  difference  to  1.0  is  attributed  to  deaths  prior  to  HSCT.  The
dashed  line  represents  patients  of  the  study  cohort  diagnosed  2010–2014  as
primary  HLH  using  flow  cytometry  screening  (n  =  38).  Patients  of  the
comparison  group  diagnosed  2003–2008  before  the  introduction  of  the
screening are shown as solid line (n = 38). Time to HSCT was shorter in the
screened  group  (median  130  days)  than  in  the  unscreened  group  (median
206  days).  The  difference  was  significant  (p  =  0.007)  in  a  competing  risk
analysis with death prior to HSCT as competing event. Among other factors, the
screening is likely to have contributed to earlier performance of HSCT
AQ2
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In recent years, new diagnostic procedures have significantly changed the
approach to patients with suspected HLH [24]. Identification of novel HLH-
associated genes has improved possibilities to definitely diagnose 1°HLH [19,
25, 26]. More specific immunological tests facilitate rapid identification of
patients in need of HSCT [12]. In addition, next-generation sequencing (NGS)
allows more comprehensive genetic analyses while offering opportunities to
identify novel genes predisposing to HLH [27]. Hence, diagnostic approaches
are changing, and the most efficient algorithm remains controversial. Here, we
prospectively evaluated the use of immunological screening as a decision tool
for genetic studies including WES. The guiding principle was to provide the
most rapid, reliable, and efficient basis for HSCT indication and other
treatment decisions in patients with suspected HLH.
We performed three-step immunological screening with intracellular protein
staining and fresh NK degranulation followed by activated NK degranulation
in patients with abnormal results. We have previously shown that the fresh
NK assay has excellent sensitivity (96%) and satisfying specificity (88%)
[12]. Although both parameters are slightly inferior with activated NK
degranulation [12], this second test improves the positive predictive value and
was therefore added to guide our decision on sequencing in this study. We did
not perform parallel cytotoxicity assays because of previously discussed
limitations [12]. We did not sequence the perforin gene in patients with
normal protein expression based on long-term experience in our and several
other laboratories (K. Gilmour, Y. Bryceson, G. de Saint Basile, personal
communication). In contrast, patients with a strong clinical suspicion for XLP
were further analyzed despite normal protein expression. This included NKT
cell quantification for XLP1 [28] and L-18 MDP stimulation for XLP2 [29],
followed by genetic analysis in those patients, where high suspicion remained.
Among 162 patients with “full” HLH in this study, 58 patients had genetic
disease. Our screening approach missed one patient with atypical CHS. It can
be argued that the limited follow-up of the patients with “full” HLH (mean of
2.4 years) is not sufficient to exclude that some patients carry clinically
relevant mutations and this remains a caveat. Among 111 patients with
“atypical/incomplete” HLH, 15 had genetic disease. All of them were picked
up by our screening approach. These findings confirm the excellent sensitivity
of immunological screening but also show that it is not 100%.
It has been suggested that because of this limited sensitivity, all patients with
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suspected HLH should undergo extensive sequencing. Such recommendations
do not consider the limitations of genetic analyses. Thus, “hidden” intronic
mutations or inversions or mutations in genes so far not associated with HLH
but affecting the same pathway are not picked up with conventional genetic
analysis. This leads to no better sensitivity of genetic compared to
immunologic analysis. Moreover, extensive sequencing, in particular in the
poorly defined cohort of patients with “incomplete” HLH, will generate many
findings that are difficult to interpret in the absence of immunological data
(such as monoallelic mutations). Restricting extensive sequencing efforts to
patients with “full” HLH is also a questionable approach. In our study, 20% of
patients with genetic disease did not present with this “classical” phenotype.
Overall, it is part of sound medical reasoning that any laboratory test
(including genetics) has limitations and must be performed and interpreted in
a clinical context. In light of the above considerations, immunological
screening appears a rational approach to determine the need and the depth of
sequencing in patients referred for evaluation for HLH. Earlier detection of
primary HLH is a further strong argument for the use of the screening tests.
We could demonstrate that the time from clinical diagnosis of HLH to HSCT
was significantly shorter after the introduction of flow cytometric screening.
There are certainly other factors that have accelerated the time to HSCT in
recent years. However, since unambiguous abnormal screening results prompt
initiation of HLA analysis and consecutive donor search within 72 h after
diagnosis, we are convinced that our screening algorithm has contributed to
this improvement.
Among those patients, where we performed genetic analysis, we detected
biallelic or hemizygous mutations in 35% of patients with “full” HLH. This is
similar to the Italian and Swedish cohorts [16, 30]. However, compared to the
Italian cohort, FHL-2 was less frequent, while albinism syndromes and FHL-3
were more frequent. Notably, 33/91 patients (36%) with 1°HLH were not
diagnosed in the context of a clinical episode fulfilling HLH criteria. This
included 18 patients diagnosed in the absence of inflammatory manifestations
and 15 patients diagnosed in the context of atypical/incomplete HLH. This
further supports the repeatedly suggested revision of diagnostic criteria for
HLH. The criteria should allow a diagnosis of 1°HLH in oligo- or
asymptomatic patients in the context of immunological findings.
In patients with abnormal immunological screening, but no mutations found in
the relevant genes and a suggestive clinical context, we extended our genetic
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analysis to WES. We identified one patient with a novel inversion in
UNC13D. Due to intronic breakpoints, this mutation had not been identified
by Sanger sequencing. In one patient, absence of albinism was the basis for
not sequencing RAB27A. We learned during this study that this should be
included, as albinism is not necessarily present in GS-2 patients [20]. We also
diagnosed one metabolic disease, Wolman disease [23]. Degranulation was
low in that patient while it was normal in her sister with the same mutation. It
remains unclear whether degranulation testing is useful in screening for this
disease; however, we had another Wolman patient with reduced degranulation
mentioned in a previous paper [12]. Only one patient was diagnosed with a
new disease associated with impaired cytotoxicity, HPS10 [21]. Together with
the findings of the Italian study [16], where 92% of patients with likely FHL
received a genetic diagnosis, this supports the assumption that at least in
European cohorts, most genes associated with impaired cytotoxicity that are
linked to an HLH phenotype in humans have been discovered.
Our focus on functional screening may have led to underdiagnosis of
monoallelic mutations. In the Italian study, 15% of patients with 2°HLH had
monoallelic mutations in HLH-associated genes [16]. A similar frequency of
monoallelic mutations was observed in a smaller Swedish cohort [30], but
such monoallelic variants were not enriched compared to healthy individuals.
Furthermore, parents or siblings with monoallelic mutations do not seem to
have a predisposition to HLH, although a slightly increased risk of
gynecological tumors has recently been demonstrated [31]. Particularly, there
is little evidence to indicate that patients carrying monoallelic mutations have
a transplant indication. This important question requires clear guidance. Based
on the available evidence, it is our policy that in the absence of significant
functional alterations [32], monoallelic mutations do not justify
transplantation. This extends to the recommendation not to transplant after a
first HLH episode in patients with homozygous A91V mutations [33, 34].
Equally, we consider carrier relatives as suitable stem cell donors and prefer a
matched sibling with a monoallelic mutation without functional abnormalities
to an unrelated wild-type donor.
Obviously, diagnostics of monogenic diseases is a field in transition. It has
been hypothesized that NGS will soon allow rapid differentiation of 1°HLH
from 2°HLH obviating the need for immunological tests [16]. We argue that
this will depend on whether this approach will become rapid enough for a
transplant decision. It will require fast workflows for individual samples that
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are cost-effective. Moreover, without functional validation, the significance of
some genetic alterations including monoallelic mutations remains unclear
[35], in particular in the absence of comprehensive and well-curated mutation
databases with clinical annotations. We therefore conclude that establishment
of reference centers for the immunological evaluation of patients with
suspected HLH is still a relevant investment into the future.
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